Therapeutic Margin, Tolerance, Harm Reduction, and Steady-State Concepts - Lecture Notes

Therapeutic Margin: ED50, LD50, and Absolute Difference

  • ED\{50} and LD\{50} are the dose metrics for efficacy and lethality, respectively.

    • ED\_{50}: dose at which 50% of the maximal therapeutic effect is observed.
    • LD\_{50}: dose at which 50% of subjects experience lethal toxicity.

  • Therapeutic margin should be thought of in absolute terms (not as a percentage):

    • Define the margin as the absolute difference between LD\{50} and ED\{50}:
      \Delta = |LD{50} - ED{50}|
    • He emphasizes that it is about absolute amounts (e.g., mg in a syringe or pill) rather than relative percentages.

  • Practical implication: a larger absolute difference means more room between therapeutic effect and lethality, regardless of proportional relationships.

  • Example discussion (from the transcript):

    • If two doses differ by 50 mg vs 500 mg, the 500 mg difference is perceived as much larger in absolute terms, implying a larger margin (but the actual safety depends on the absolute amounts and context).
    • The key question is: which absolute difference is safer: 50\,\text{mg} or 500\,\text{mg}? The latter is numerically larger, but safety depends on pharmacology, not just the size of the difference.

  • Relative to real-world drug safety, absolute margins can change with dose form and potency (e.g., highly potent substances require careful consideration of tiny absolute changes).

Tolerance: Three Types and Their Effects on the Margin

  • Tolerance means the body requires more drug to achieve the same effect.

  • Three kinds of tolerance discussed:

    • Pharmacokinetic tolerance: changes in drug metabolism/elimination (e.g., faster clearance).
    • Pharmacodynamic tolerance: changes at the drug's site of action (receptors), e.g., receptor desensitization or downregulation.
    • Behavioral tolerance: learned or adaptive changes in behavior that affect drug response.

  • The affected dose changes in response to tolerance: the participant tends to take more to achieve the same effect (i.e., the effective dose increases).

  • Both ED\{50} and LD\{50} can change with tolerance, but not necessarily at the same rate or on the same receptors:

    • Different brain regions (e.g., brainstem vs forebrain) and different receptor types may develop tolerance differently.
    • If brainstem receptors (potentially metabotropic) adapt differently than forebrain receptors, ED\{50} and LD\{50} can diverge, shrinking the therapeutic margin over time.

  • Hypothetical framing: if the ED\{50} grows faster than the LD\{50}, the margin
    \Delta = |LD{50} - ED{50}|
    may shrink, making the drug more dangerous despite a larger absolute difference in some other sense.

  • Practical implications:

    • In opioid treatment, the interaction of tolerance at different receptor populations (e.g., metabolically vs receptor-level tolerance) affects safety margins.
    • Consider metabotropic vs ionotropic receptors and their differential tolerance profiles.
    • The same drug could have shifting ED\{50} and LD\{50} due to pharmacokinetic changes (e.g., liver metabolism) and pharmacodynamic changes (receptor sensitivity).

Historical and Real-World Context: Opiates, Overdose, and Potency

  • Historical misunderstanding of overdose during heroin outbreaks (late 1950s–1960s):

    • Overdose was often treated as a sign of despondent suicide rather than a pharmacological issue.
    • In reality, street heroin was adulterated with unknown substances; purity varied; potency could be extremely high due to unknown contaminants.
    • This lack of precision in pharmacology and drug composition altered the ED/LD relationship, bringing them closer in practice.

  • The fentanyl era changed the dynamic dramatically:

    • Fentanyl is measured in micrograms, increasing potency and reducing the absolute amounts needed for effect or lethality.
    • New synthetic opioids with very small LD\_{50} values relative to common opioids shift safety margins and raise overdose risk even with small dosing errors.

  • Key takeaway: no single absolute dose is universally safe; margins depend on potency, adulterants, pharmacokinetics, and individual variability.

Harm Reduction: Connecting ED/LD to Safer Use

  • Harm reduction acknowledges ongoing use but aims to minimize harm and death.

  • Core ideas:

    • People will use drugs regardless of legality or stigma; safer use practices can reduce risk.
    • Services may include testing/test kits, clean needles, hotlines, and on-site drug checking in some places.

  • How LD/ED concepts fit harm reduction:

    • Baseline variability makes universal preset LD/ED values unhelpful; individualized information and purity testing help users avoid lethal doses.
    • Testing for purity and potency (on-site assays) can provide immediate feedback to reduce overdose risk.

  • Important distinction:

    • Harm reduction aims to keep people alive while they pursue change, not solely to promote abstinence.
    • The approach can be part of a pathway toward treatment and reduced dependence.

  • Practical considerations raised in the discussion:

    • LD/ED figures are highly individualized due to metabolism, receptor expression, and duration of use.
    • Long-term users may have shifting baseline tolerances; a static LD/ED test kit cannot capture dynamic changes without context or history.
    • In real-world settings, there is no universal cutoff; clinicians must consider patient history, current health status, and potential adulterants.

Pharmacokinetics and Pharmacodynamics: Steady State and Dosing Strategies

  • Steady-state concept: when dosing is repeated, the average drug exposure stabilizes; peak and trough levels settle within a range.
  • Key variables:
    • Dose (
      D"))
    • Bioavailability (F)
    • Volume of distribution (V_d)
    • Elimination rate constant (k)
    • Half-life (
      t_{1/2} = \frac{\ln 2}{k}
    • Dosing interval (\tau)
  • Relationship between dosing and steady state (one-compartment model):
    • Peak concentration at steady state:
      C{max,ss} = \frac{F D}{Vd} \frac{1}{1 - e^{-k \tau}}
    • Trough concentration at steady state:
      C{min,ss} = C{max,ss} \; e^{-k \tau}
    • Steady state typically reached after about 4-5 half-lives:
      t{ss} \approx 4-5\, t{1/2}
  • Practical insight from the lecture:
    • A common example uses a 100 mg tablet with assumed F ≈ 1 and a half-life of 24 hours:
    • If you dose once daily, after a day the peak might be around 100 (in arbitrary units), and by the next day, the trough reduces to about 50, illustrating the concept of steady state and the need to maintain levels above ED{50} but below LD{50} for therapeutic benefit without toxicity.
  • Dosing strategy implications:
    • Start low and titrate up to minimize secondary effects; jumping to a high dose can cause unsafe peaks.
    • If a single daily dose cannot maintain levels above ED{50} without approaching LD{50}$$, consider split dosing or long-acting formulations.
  • Example: ADHD medications with long-acting release may involve two-tablet regimens to smooth effects and manage side effects.

Real-World Drugs and Tolerance: Concrete Examples

  • Librium (Chlordiazepoxide):
    • Tolerance can occur to the sedative effect, while some other effects may not show the same tolerance pattern.
    • This means sedation may decrease over time, allowing safer functioning; however, other risks (e.g., dependence, cognitive impairment) remain.
  • Relevance to sedation and safety:
    • Different drugs exhibit different tolerance profiles; the therapeutic margin can widen or shrink depending on which effects are tolerated.
  • Pharmacokinetic changes with age:
    • In older adults, metabolic changes can shift clearance and distribution, altering effective doses and margins.
  • Poly-drug environments:
    • Street drugs may be combined in ways that produce non-additive or unpredictable effects; sellers may not optimize for a consistent pharmacodynamic profile.
  • Numerical example lines from the talk:
    • A dose of 150 mg may be considered a large margin in some contexts, while others could tolerate higher doses depending on metabolism and receptor sensitivity.

Safety and Neurobiology: SSRIs, Neurogenesis, and Reuptake

  • SSRIs and brain plasticity:
    • The lecturer suggests that SSRIs may foster brain repair and growth by elevating serotonin levels, contributing to neuroplastic changes.
    • The exact clinical implications (e.g., neurogenesis in the hippocampus) are framed as a theoretical model in the talk.
  • Reuptake blockade and neural activity:
    • Blocking reuptake increases synaptic serotonin (and other monoamines), generally increasing neural activity in certain circuits.
    • The contrast between ionotropic (ligand-gated, fast) channels and metabotropic (G-protein-coupled, slower, modulatory) receptors is discussed:
    • Ionotropic receptors are fast-acting; metabotropic receptors produce longer-lasting modulatory effects.
  • Open questions raised in class:
    • If SSRIs promote neuroplasticity, to what extent does that translate to clinically meaningful recovery in depression-related neurobiology?
    • How do different receptor types and brain regions respond to tolerance, treatment, and experiment-based interventions?

Procedure, Tests, and Class Discussion: A Snapshot

  • Test procedures and procedures around measuring ED/LD dependencies were promised to be covered; the instructor noted:
    • There will be a discussion of test procedures and some differences in approaches across sections.
  • Steady-state concentration and practical context:
    • The dialogue emphasizes the mismatch that can occur between theoretical steady-state calculations and real-world patient variability.
  • Personal inventory activity:
    • A reflective exercise asking students to consider where they stood on a given date (August 18) regarding primary effects and lethality, linking the theoretical framework to personal context.

Quick Real-World Takeaways

  • Therapeutic margin is best understood as an absolute difference in dose space, not a percentage.
  • Tolerance evolves through multiple mechanisms and can shift both ED\{50} and LD\{50}, but not necessarily equally across brain regions or receptor types.
  • In high-potency drugs (e.g., fentanyl) very small absolute changes can mean large shifts in safety risk; pure reliance on intuitive “more safe” thinking can fail.
  • Harm reduction emphasizes safety, measurement, and survival as steps toward broader public health goals.
  • Steady-state concepts provide a framework for dosing strategies, but individual variability necessitates cautious titration and monitoring.
  • Neurobiology and pharmacology intersect in complex ways (SSRIs, neurogenesis, reversal of tolerance, receptor types), highlighting ongoing debate and inquiry in education and clinical practice.